Some of the more popular treatments for type 2 diabetes directly target circulating glucose concentrations and include pharmacological agents such as metformin, which reduces hepatic glucose production, or glibenclamide, which increases pancreatic insulin release. This evidence concerns the gene INS and type 2 diabetes mellitus.